Assessment of Pentraxin 3 (PTX3) and Sclerostin (SOST) Levels in Serum of Patients with Chronic Kidney Disease


  • Wijdan Rajh Hamza Al-Kraity



Chronic Kidney disease (CKD), Pentraxin 3 (PTX3) and Sclerostin (SOST)


In the present study, 70 of patients were 35 males and 35 females were suffering from chronic kidney
disease, and 20 of control group. The samples were collected from Specialized Center for Diseases and
Kidney Transplant in AL-Sadder Medical City/Najaf Governorate/Iraq, during the period from July till
August, 2019. The ages of control and patients ranged 30 to 69 y old. The patients group was divided into
subgroup according to the age and gender, Patients without a complete medical record were excluded and
those with other diseases were excluded.
The present study revealed a significant enhance (p<0.05) inserum PTX3 and SOST levels in CKD compare
with control group, while a significant decline (P<0.05) in serum HDL level of CKD in comparison with
control group. The result indicated no significant differences (p>0.05) in serum of PTX3 and SOST levels
between female and males groups of CLD patients. Also, The results showed a significant increase (p>0.05)
in serum PTX3 and SOST levels there was a significant increase(p<0.05)among different groups ages. There
is a positive association between PTX3 and SOST concentrations of CKD patients
Conclusion: The current study conducted that PTX3 and SOST levels were good markers for diagnosis and
detection of chronic kidney disease in both genders the males and females.

Author Biography

Wijdan Rajh Hamza Al-Kraity

Ph.D. in Medical Physiology, Department Medical Laboratories Techniques, Al-Toosi University College



How to Cite

Wijdan Rajh Hamza Al-Kraity. (2021). Assessment of Pentraxin 3 (PTX3) and Sclerostin (SOST) Levels in Serum of Patients with Chronic Kidney Disease. Medico Legal Update, 21(2), 1274-1280.